Aposense

company

About

Aposense is a molecular imaging and drug development company, with a pipeline of products, based on its apoptosis-based technology.

  • 1 - 10

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$7.30M
Industries
Biotechnology,Health Care,Medical,Pharmaceutical
Founded date
Jan 1, 1996
Number Of Employee
1 - 10
Operating Status
Active

Aposense (formerly NST) is a clinical-stage molecular imaging and drug development company, with a pipeline of products based on its patented platform technology for targeting apoptosis (programmed cell death) in vivo. The company translating the science of Apoptosis (programmed cell death) into personalized patient care in multiple disease categories, including oncology, cardiology, and neurology. Targeting of this important biological process in-vivo opens opportunities for real-time clinical imaging of disease activity and targeted therapy.

Aposense specializing in the development of novel drugs and utilizing membrane electrical forces for trans-membrane of macromolecule drugs, mainly siRNA. It also developed rationally-designed molecular nano-motors (MNMs), being novel small-molecule chemical entities and its translation into kinetic energy for movement within the hydrophobic membrane core.

Aposense was founded in 1996 and is headquartered in Petah Tiqva, HaMerkaz, Israel.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$22.30M
Aposense has raised a total of $22.30M in funding over 2 rounds. Their latest funding was raised on May 23, 2010 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 23, 2010 Series Unknown $3M 1 Ziegler Meditech Equity Partners Detail
Aug 20, 2008 Series Unknown $7.30M 5 Detail
Nov 9, 2006 Series Unknown $12M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
5
Aposense is funded by 5 investors. Ziegler Meditech Equity Partners and Bargal R&D Investment are the most recent investors.
Investor Name Lead Investor Funding Round
Ziegler Meditech Equity Partners Yes Series Unknown
Bargal R&D Investment Series Unknown
Polar Investments Series Unknown
Federman & Sons Series Unknown
Phoenix Insurance Series Unknown